GenVec, Inc., a biopharmaceutical company, develops gene-based therapeutic drugs and vaccines. The company’s gene-based therapeutic product candidates use its proprietary adenovector technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. Its lead product candidate, TNFerade Biologic, is an adenovector that contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with anti-cancer effects. Administered by injection directly into tumors, TNFerade Biologic stimulates the production of TNF-alpha in the tumor. GenVec is developing TNFerade Biologic, which is in phase II/III clinical trial for use in...